文献速递认知障碍与痴呆

既往创伤性脑损伤与阿尔茨海默病血液标志物

Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers.
PubMed 文献 · JAMA Neurol · 2026-01-01

该横断面队列研究评估了血浆p-tau217/Aβ42比值在有无TBI史的退伍军人中检测脑淀粉样蛋白PET阳性的准确性。272名参与者中,无TBI者准确性为90%,而TBI伴意识丧失0-5分钟者为78%,大于5分钟者仅63%。在认知正常或轻度认知障碍且有TBI史者中,该检测可能漏诊超过一半的淀粉样PET阳性病例。

要点

  • 血浆p-tau217/Aβ42比值在无TBI退伍军人中检测淀粉样PET阳性准确性达90%。
  • TBI伴意识丧失0-5分钟者准确性降至78%,大于5分钟者降至63%。
  • 有TBI史者中该检测可能漏诊超过一半的淀粉样PET阳性病例,需谨慎解读。

核心结论

  • 在认知正常或轻度认知障碍且有TBI史的退伍军人中,血浆p-tau217/Aβ42比值检测可能漏诊超过一半的淀粉样PET阳性病例,应谨慎解读AD血液检测结果。

研究设计与样本

  • 横断面队列诊断试验,使用ADNI-DOD研究2013至2020年入组的272名无痴呆越南战争退伍军人(认知正常或轻度认知障碍),均有淀粉样PET和同期储存血浆。

主要发现

  • 272名参与者平均年龄70岁(SD 4.5),270名为男性(99.3%),83名(30.5%)为淀粉样PET阳性。
  • 血浆p-tau217/Aβ42比值在无TBI退伍军人中准确性为90%(95% CI 84%-96%)。
  • 单独血浆p-tau217和血浆Aβ42/40比值结果相似,排除近10年内TBI或改用定量阈值定义淀粉样PET阳性后结果仍相似。

临床怎么用

  • 对于有TBI史的认知正常或轻度认知障碍患者,解读AD血液标志物(如p-tau217/Aβ42比值)时需警惕假阴性可能。

局限性

  • 研究为横断面设计,样本以男性退伍军人为主(99.3%),外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Traumatic brain injury (TBI) is a risk factor for dementia and is known to impact levels of several Alzheimer disease (AD) blood biomarkers. The plasma phosphorylated tau 217 (p-tau217)/amyloid-β 42 (Aβ42) ratio has been reported to be 90% accurate for the detection of brain amyloid in civilian cohorts. OBJECTIVE: To evaluate the accuracy of emerging AD blood biomarkers in veterans with and without a TBI history. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional cohort study of a diagnostic test assessed the performance of the US Food and Drug Administration-approved plasma p-tau217/Aβ42 ratio and plasma levels of p-tau217 and Aβ42/40 ratio for detecting brain Aβ positivity (eg, amyloid-positron emission tomography [PET] consensus visual read). The accuracy of biomarkers was compared in veterans without TBI, those with TBI with loss of consciousness (LOC) for 0 to 5 minutes, and those with TBI with LOC for greater than 5 minutes. Existing data and banked plasma from the Alzheimer Disease Neuroimaging Initiative Department of Defense (ADNI-DOD) study were used. Years of enrollment were 2013 to 2020. Included in this study were Vietnam War veterans without dementia (cognitively unimpaired and those with mild cognitive impairment) who had amyloid-PET and concurrently collected banked plasma available for analysis. Plasma biomarker analysis took place from 2024 to 2025, and data analysis was performed from July 2025 to February 2026. EXPOSURES: AD blood biomarkers and TBI history. MAIN OUTCOMES AND MEASURES: p-Tau217/Aβ42 accuracy in the detection of amyloid-PET consensus visual read positivity across groups with/without TBI exposure. RESULTS: In 272 participants, mean (SD) age was 70 (4.5) years, 270 were male (99.3%), and 83 (30.5%) were amyloid-PET positive. The plasma p-tau217/Aβ42 ratio was highly accurate in veterans with no TBI (90%; 95% CI, 84%-96%) but not in veterans with TBI with LOC for 0 to 5 minutes (78% accuracy; 95% CI, 69%-87%; P = .03 vs no TBI), nor in veterans with TBI with LOC greater than 5 minutes (63% accuracy; 95% CI, 53%-73%; P < .001 vs no TBI). Results were similar for plasma p-tau217 alone and plasma Aβ42/40 ratio. Results were also similar after excluding veterans with TBI within the past 10 years or when amyloid-PET positivity was defined using a quantitative threshold rather than consensus visual read. CONCLUSIONS AND RELEVANCE: Results of this cross-sectional cohort study of a diagnostic test suggest that among individuals who are cognitively unimpaired or have mild cognitive impairment and a TBI history, the p-tau217/Aβ42 ratio test may miss over half of amyloid-PET-positive cases. Caution is advised in interpreting AD blood test results in this context.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Rosen-Lang Y, Vrillon A, Pasternak S, et al. Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers. JAMA Neurol. 2026. PMID: 42371653. doi:10.1001/jamaneurol.2026.2042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。